Results 111 to 120 of about 68,100 (329)

Alpha Synuclein Toxicity and Non-Motor Parkinson’s

Cells
Parkinson’s disease (PD) is a common multisystem neurodegenerative disorder affecting 1% of the population over the age of 60 years. The main neuropathological features of PD are the loss of dopaminergic neurons in the substantia nigra pars compacta ...
Gabriella M. Mazzotta, Carmela Conte
doaj   +1 more source

Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type. [PDF]

, 2017
Amyloid aggregates found in the brain of patients with neurodegenerative diseases, including Alzheimer's and Parkinson's disease, are thought to spread to increasingly larger areas of the brain through a prion-like seeding mechanism.
Esko, Jeffrey D, Ihse, Elisabet, Lawrence, Roger, Masliah, Eliezer, van Wijk, Xander M, Yamakado, Hodaka   +5 more
core   +2 more sources

Alternative Pathway for Methyl Supply through the Coupling of SHMT1 and PEMT to Maintain Astrocytic Homeostasis in Parkinson's Disease

Advanced Science, EarlyView.
In Parkinson's disease, SHMT1 downregulation disrupts its interaction with PEMT in astrocytes, reducing SAM levels. This leads to H3K4me1 hypomethylation and decreased Slc1a2/Glul expression, ultimately exacerbating neuroexcitotoxicity and dopaminergic neuron loss.
Yue‐Han Chen, Rong‐Xin Zhu, Nuo‐Xi Zhang, Ting‐Ting Sun, Xi‐Wei Zhang, Yu‐Jie Zhao, Ben‐Yu He, Hang Yao, Ren‐Hong Du, Lei Cao, Wen‐Bin Zhang, Wei‐Guo Liu, Yun Cai, Cong Wang, Gang Hu, Yao Wei, Yang Liu, Ming Lu   +17 more
wiley   +1 more source

Ghrelin receptor agonist rescues motor impairments and protects dopamine neurons in alpha-synuclein aggregation model

, 2023
K. Maziarz, M. Jankowska-Kieltyka, J. Barut, P. Chmielarz   +3 more
openalex   +1 more source

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson\u27s Disease. [PDF]

, 2019
While GM1 may interact with α-synuclein in vitro to inhibit aggregation, the ability of GM1 to protect against α-synuclein toxicity in vivo has not been investigated.
Aras, Radha, Brotchie, Jonathan M., Koprich, James B., Schneider, Jay S., Singh, Vikrant, Williams, Courtney K.   +5 more
core   +1 more source

Simultaneous Inference in General Parametric Models [PDF]

, 2008
Simultaneous inference is a common problem in many areas of application. If multiple null hypotheses are tested simultaneously, the probability of rejecting erroneously at least one of them increases beyond the pre-specified significance level ...
Bates, Bates, Bretz, Bretz, Bullinger, Bönsch, Garcia, Genz, Genz, Genz, Hochberg, Hothorn, Hothorn, Hsu, Marcus, R Development Core Team, Rousseeuw, Salib, Searle, Serfling, Shaffer, Stefanski, Todorov, Tong, Westfall, Westfall, Westfall, Yohai, Zeileis, Zeileis   +29 more
core   +3 more sources

Crossing the Blood–Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy

Advanced Science, EarlyView.
Molecularly imprinted polymeric nanocarriers (nanoMIPs) offer robust, antibody‐mimetic platforms to overcome the blood‐brain barrier. The article surveys nanoMIP design and ligand‐directed surface engineering that harness receptor‐mediated transcytosis, and highlights therapeutic and diagnostic applications in neurodegeneration, brain tumors and ...
Ranjit De, Shuliang Shi, Kyong‐Tai Kim
wiley   +1 more source

Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson disease cell models

Neurobiology of Disease
Objective: Parkinson's disease (PD) pathophysiology is associated with a progressive loss of dopaminergic neurons in the substantia nigra and accumulation of insoluble inclusions of misfolded alpha-synuclein.
Sara Lucas-Del-Pozo, Giuseppe Uras, Federico Fierli, Veronica Lentini, Sofia Koletsi, Carlos Lazaro-Hernandez, Kai-Yin Chau, Derralynn A. Hughes, Anthony H.V. Schapira   +8 more
doaj   +1 more source

Disease modifying therapy for multiple system atrophy – Parkinsonian Type [PDF]

, 2017
BACKGROUND: Multiple System Atrophy –Parkinsonian Type (MSA-P) is a rare, rapidly progressive neurodegenerative disease without any current treatment.
Dwyer, Sean Sullivan
core  

Substituent‐Based Modulation of Self‐Assembly and Immunogenicity of Amphipathic Peptides

Advanced Science, EarlyView.
This study systematically investigates how positional and subtle changes, such as substituents on the phenyl ring attached to short amphipathic peptides, influence their self‐assembly, fibril morphology, and immunogenic responses. ABSTRACT Self‐assembled peptide‐based biomaterials provide versatile platforms for biomedical uses, featuring customizable ...
Anirban Das, Ushasi Pramanik, Elise M. Brown, Chih‐Yun Liu, Huan Gong, Jonathan Fascetti, Mark Gibson, Samuel Stealey, Silviya P. Zustiak, Cory Berkland, Piyoosh Sharma, Meredith E. Jackrel, Mark A. White, Jai S. Rudra   +13 more
wiley   +1 more source